Selected research
Market Structure
Global Tafamidis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Tafamidis Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Tafamidis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Tafamidis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Tafamidis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Tafamidis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Tafamidis Drugs include Pfizer, Qilu pharmaceutical and Chia Tai Tianqing Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Tafamidis Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Tafamidis Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Tafamidis Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tafamidis Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Tafamidis Drugs Segment by Company
Pfizer
Qilu pharmaceutical
Chia Tai Tianqing Pharmaceutical
Tafamidis Drugs Segment by Type
Tafamidis Free Acid
Tafamidis Meglumine
Tafamidis Drugs Segment by Application
ATTR-PN
ATTR-CM
Other
Tafamidis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tafamidis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tafamidis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tafamidis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Tafamidis Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tafamidis Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Tafamidis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Tafamidis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tafamidis Free Acid
- Tafamidis Meglumine
Applications
- ATTR-PN
- ATTR-CM
- Other
Companies covered
- Pfizer
- Qilu pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Tafamidis Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Tafamidis Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Tafamidis Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Tafamidis Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Tafamidis Drugs Market Dynamics
- 2.1 Tafamidis Drugs Industry Trends
- 2.2 Tafamidis Drugs Industry Drivers
- 2.3 Tafamidis Drugs Industry Opportunities and Challenges
- 2.4 Tafamidis Drugs Industry Restraints
3 Tafamidis Drugs Market by Manufacturers
- 3.1 Global Tafamidis Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Tafamidis Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Tafamidis Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Tafamidis Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Tafamidis Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Tafamidis Drugs Manufacturers, Product Type & Application
- 3.7 Global Tafamidis Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Tafamidis Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Tafamidis Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Tafamidis Drugs Tier 1, Tier 2, and Tier 3
4 Tafamidis Drugs Market by Type
- 4.1 Tafamidis Drugs Type Introduction
- 4.1.1 Tafamidis Free Acid
- 4.1.2 Tafamidis Meglumine
- 4.2 Global Tafamidis Drugs Sales by Type
- 4.2.1 Global Tafamidis Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Tafamidis Drugs Sales by Type (2021-2032)
- 4.2.3 Global Tafamidis Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Tafamidis Drugs Revenue by Type
- 4.3.1 Global Tafamidis Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Tafamidis Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Tafamidis Drugs Revenue Market Share by Type (2021-2032)
5 Tafamidis Drugs Market by Application
- 5.1 Tafamidis Drugs Application Introduction
- 5.1.1 ATTR-PN
- 5.1.2 ATTR-CM
- 5.1.3 Other
- 5.2 Global Tafamidis Drugs Sales by Application
- 5.2.1 Global Tafamidis Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Tafamidis Drugs Sales by Application (2021-2032)
- 5.2.3 Global Tafamidis Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Tafamidis Drugs Revenue by Application
- 5.3.1 Global Tafamidis Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Tafamidis Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Tafamidis Drugs Revenue Market Share by Application (2021-2032)
6 Global Tafamidis Drugs Sales by Region
- 6.1 Global Tafamidis Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Tafamidis Drugs Sales by Region (2021-2032)
- 6.2.1 Global Tafamidis Drugs Sales by Region (2021-2026)
- 6.2.2 Global Tafamidis Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Tafamidis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Tafamidis Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Tafamidis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Tafamidis Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Tafamidis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Tafamidis Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Tafamidis Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Tafamidis Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Tafamidis Drugs Revenue by Region
- 7.1 Global Tafamidis Drugs Revenue by Region
- 7.1.1 Global Tafamidis Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Tafamidis Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Tafamidis Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Tafamidis Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Tafamidis Drugs Revenue (2021-2032)
- 7.2.2 North America Tafamidis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Tafamidis Drugs Revenue (2021-2032)
- 7.3.2 Europe Tafamidis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Tafamidis Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Tafamidis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Tafamidis Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Tafamidis Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Pfizer
- 8.1.1 Pfizer Company Information
- 8.1.2 Pfizer Business Overview
- 8.1.3 Pfizer Tafamidis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Pfizer Tafamidis Drugs Product Portfolio
- 8.1.5 Pfizer Recent Developments
- 8.2 Qilu pharmaceutical
- 8.2.1 Qilu pharmaceutical Company Information
- 8.2.2 Qilu pharmaceutical Business Overview
- 8.2.3 Qilu pharmaceutical Tafamidis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Qilu pharmaceutical Tafamidis Drugs Product Portfolio
- 8.2.5 Qilu pharmaceutical Recent Developments
- 8.3 Chia Tai Tianqing Pharmaceutical
- 8.3.1 Chia Tai Tianqing Pharmaceutical Company Information
- 8.3.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 8.3.3 Chia Tai Tianqing Pharmaceutical Tafamidis Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Chia Tai Tianqing Pharmaceutical Tafamidis Drugs Product Portfolio
- 8.3.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Tafamidis Drugs Value Chain Analysis
- 9.1.1 Tafamidis Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Tafamidis Drugs Production Mode & Process
- 9.2 Tafamidis Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Tafamidis Drugs Distributors
- 9.2.3 Tafamidis Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst